ANDS Related Analyst Ratings
-
Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
-
National Securities Initiates Coverage on Anadys Pharmaceuticals (ANDS) with a Buy
-
Wedbush Assumes and Initiates Coverage on Several Key Biotech Players in Anti-Viral Space
-
ThinkEquity Upgrades Anadys Pharmaceuticals (ANDS) to Accumulate
-
ThinkEquity Upgrades Anadys Pharma (ANDS) to Buy
-
Oppenheimer Initiates Coverage on Anadys Pharmaceuticals (ANDS)
-
Piper Jaffray Maintains a 'Buy' on Anadys Pharmaceuticals (ANDS), Adds To The Alpha List
-
Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Buy
-
ThinkPanmure Initiates Coverage on Anadys (ANDS) with a Buy
-
Merriman Curhan Initiates Coverage on Anadys Pharmaceuticals (ANDS)
-
JMP Starts Anadys Pharma (ANDS) at Market Outperform
-
Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Neutral
-
IDP, ANDS, DVAX Could See Action Related to Pfizer's Deal to Acquire Coley
-
Merriman Curhan Starts Anadys Pharmaceuticals (ANDS) at Neutral
-
Stifel Nicolaus downgrades Anadys (ANDS) to Sell
-
Piper Jaffray downgrades Anadys Pharmaceuticals, Inc. (ANDS) to Underperform
-
ThinkEquity downgrades Anadys (ANDS) to Sell
-
ThinkEquity Starts Anadys Pharma (ANDS) at Accumulate
-
Deutsche Bank Initiates Coverage on ANDS With a Buy
-
JP Morgan Initiates ANDS
-
Susquehanna Initiates ANDS
-
CSFB Starts ANDS at Outperform
-
Needham Raises its Price Target on ANDS
-
JMP Securities Started ANDS at Strong Buy
-
Piper Jaffray Raises Price Target on ANDS To $15
Back to ANDS Stock Lookup
